HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adams, C. Articles by Lewis, R. Search for Related Content PubMed PubMed Citation Articles by Adams, C. Articles by Lewis, R.

Drug treatments for schizophrenia

Cochrane Schizophrenia Group, Oxford, UK

Paul Wilson, research fellow, Simon Gilbody, research fellow, Anne-Marie Bagnall, research fellow, Ruth Lewis, research fellow

NHS Centre for Reviews and Dissemination, University of York,

Paul Wilson, NHS Centre for Reviews and Dissemination, University of York, York YO1 5DD, UK Email: pmw7@york.ac.uk This paper summarises the research evidence presented in a recent issue of Effective Health Care on drug treatments for schizophrenia.¹

Background

Schizophrenia is an illness or a group of illnesses affecting language, planning, emotion, perceptions, and movement. In the UK, approximately 250 000 people suffer from schizophrenia or a schizophrenia-like illness.²

A quarter of those who have experienced an episode of schizophrenia recover and the illness does not recur. Another 25% experience an unremitting illness. The remaining 50% have a recurrent illness, but with long episodes of considerable recovery from positive symptoms such as delusions, hallucinations, disordered thinking, and catatonic movements.³ Many with recurrent illness have enduring problems from schizophrenia such as persistent psychotic symptoms, but, for most people, the problems consist of negative symptoms such as loss of enthusiasm and emotional responsiveness, apathy, and social withdrawal.³ These negative symptoms, though intrinsic to schizophrenia, are compounded by the adverse effects of . . . [Full text of this article]

This article has been cited by other articles:

				Y. Kozuki and E. S. Froelicher Lack of Awareness and Nonadherence in Schizophrenia West J Nurs Res, February 1, 2003; 25(1): 57 - 74. [Abstract] [PDF]